Is Aclaris Therapeutics, Inc. (ACRS) Overvalued?
We dive into why Aclaris Therapeutics, Inc. (ACRS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Commentary & Analysis
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 5.82%
As of Thursday, August 06, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 5.82%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.88%
As of Tuesday, August 04, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.88%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.54%
As of Thursday, July 09, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.54%, which has investors questioning if this is right time to sell.Michael Rose
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.68%
As of Tuesday, June 23, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $931.8 | $618.0 | 44% |
|
| Shares Out (Mil) | 142.7 | 44.8 | 70% |
|
| Institutional Ownership | 96.7% | 85.3% | 71% |
|
| Float (Mil) | 109.9 | 47.4 | 63% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 1,454 | 390 | 77% |
|
| Price Change (52-week) |
253.6% | 68.6% | 98% |
|
| Growth | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.7% | 6.7% | 30% |
|
| Net Income (5yr) | (4.9%) | (1.6%) | 34% |
|
| EPS (5yr) | 15.1% | 14.9% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 34.4% | (14.9%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 10 | |
| Current EPS | ($0.167) | ($0.651) | ($0.812) | |
| Month Ago EPS | ($0.173) | ($0.655) | ($0.829) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.164) | ($0.636) | ($0.726) | |
| Year/Year Chg | 10.6% | 22.8% | 53.2% | |
| Financials | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $291 | 8% |
|
| Net Income (TTM) (Mil) | ($76) | ($11) | 13% |
|
| EPS (TTM) | ($0.586) | ($0.700) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $5 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 18% |
|
| Enterprise Value (Q1) (Mil) | na | $450 | na |
|
| Valuation | ACRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.11 | 2.78 | 85% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (757.7%) | 67.0% | 0% |
|
| Net Margin | (921.5%) | (2.3%) | 0% |
|
| ROA | (41.1%) | (22.4%) | 13% |
|
| ROE | (59.1%) | (20.2%) | 14% |
|
| Liabilities to Assets | 30.7% | 32.2% | 22% |
|
| F-Score | 3 | 3 | 18% |
|
Aclaris Therapeutics, Inc. did not pass any screens on 8/20/2026.
